Incannex appoints principal investigators for ihl-42x phase 2/3 clinical trial

Melbourne, australia, june 16, 2023 (globe newswire) -- incannex healthcare limited (nasdaq: ixhl) (asx: ihl), (‘incannex' or the ‘company') a clinical-stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for unmet medical needs, is pleased to announce that it has recruited two highly experienced lead principal investigators (pis) for the ind opening phase 2/3 clinical trial investigating ihl-42x for treatment of obstructive sleep apnoea (‘osa'). dr john d hudson of futuresearch trials of neurology, austin, texas and dr russell rosenberg of neurotrials research inc, atlanta, georgia.
IXHL Ratings Summary
IXHL Quant Ranking